Immix Biopharma Files Definitive Proxy Statement
Ticker: IMMX · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 1873835
| Field | Detail |
|---|---|
| Company | Immix Biopharma, INC. (IMMX) |
| Form Type | DEF 14A |
| Filed Date | Apr 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, pharmaceutical
TL;DR
Immix Biopharma just dropped its proxy statement. Nothing new, just standard filings.
AI Summary
Immix Biopharma, Inc. filed its definitive proxy statement (DEF 14A) on April 30, 2025, for the fiscal year ending December 31, 2024. The filing indicates no fee was required for this submission. The company is based in Los Angeles, California, and operates in the pharmaceutical preparations sector.
Why It Matters
This filing is a standard regulatory requirement for public companies, providing shareholders with information necessary for upcoming shareholder meetings and voting.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing, which is a standard disclosure document and does not inherently present new risks.
Key Numbers
- 2024-12-31 — Fiscal Year End (The reporting period for this proxy statement.)
- 20250430 — Filing Date (The date Immix Biopharma, Inc. filed this document with the SEC.)
Key Players & Entities
- Immix Biopharma, Inc. (company) — Registrant
- 0001873835 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
- 454869378 (company) — EIN
- DE (company) — State of Incorporation
- 1231 (company) — Fiscal Year End
- 11400 WEST OLYMPIC BLVD. SUITE 200 (company) — Business Address
- LOS ANGELES (company) — City
- CA (company) — State
- 90064 (company) — ZIP Code
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is a document filed with the SEC by a company that is soliciting shareholder votes for matters such as annual meetings, director elections, or other corporate actions.
When is the fiscal year end for Immix Biopharma, Inc. as indicated in this filing?
The fiscal year end for Immix Biopharma, Inc. is December 31, as stated in the filing.
What is the filing date of this Definitive Proxy Statement?
The Definitive Proxy Statement was filed on April 30, 2025.
Does Immix Biopharma, Inc. have a fee associated with this filing?
No, the filing explicitly states 'No fee required'.
What industry does Immix Biopharma, Inc. operate in?
Immix Biopharma, Inc. operates in the Pharmaceutical Preparations industry, indicated by the SIC code 2834.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 regarding Immix Biopharma, Inc. (IMMX).